Prostate Cancer Foundation awards $30M in new funding for innovative research

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

West African genetic ancestry was associated with increased prostate cancer among men living in disadvantaged neighborhoods but not among men living in more affluent neighborhoods, according to a new study led by NIH researchers. The findings suggest that neighborhood environment may play a role in determining how genetic ancestry influences prostate cancer risk.

September 20, 2024

Vol.50 No.35

Clinical Roundup

New AI model can prevent unnecessary prostate removals

A research team at MedUni Vienna developed a method which utilizes multi-omics and machine learning to identify prostate cancer patients for whom surgical treatment is the best option, potentially avoiding unnecessary surgery in patients with a lower risk of tumor spread.

September 13, 2024

Vol.50 No.34

Clinical Roundup

Study confirms AI outperforms conventional methods for prostate cancer ECE

A study recently published in BJUI Compass found that Unfold AI, an FDA-cleared artificial intelligence algorithm developed by Avenda Health, accurately predicted extracapsular extension risk (ECE) and outperformed conventional methodologies.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Updated ArteraAI Prostate Test informs active surveillance decisions for lower-risk prostate cancer

Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced an update to the ArteraAI Prostate Test, enabling clinicians to make more informed decisions about active surveillance when delivering care to prostate cancer patients.

August 09, 2024

Vol.50 No.32

Clinical Roundup

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

DNA/RNA material contained in circulating extracellular vesicles secreted into the bloodstream by tumor cells captures cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a new study.

July 26, 2024

Vol.50 No.30

Drugs & Targets

FDA accepts Telix’s NDA for prostate cancer imaging agent

FDA has accepted the filing of Telix Pharmaceuticals Limited’s New Drug Application for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer.

July 26, 2024

Vol.50 No.30

Prostate Cancer Foundation awards $30M in new funding for innovative research

YOU MAY BE INTERESTED IN

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

New AI model can prevent unnecessary prostate removals

Study confirms AI outperforms conventional methods for prostate cancer ECE

Updated ArteraAI Prostate Test informs active surveillance decisions for lower-risk prostate cancer

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

FDA accepts Telix’s NDA for prostate cancer imaging agent

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login